Veru Inc Newsroom

The Past Three Years for Veru (NASDAQ:VERU) Investors Has Not Been Profitable

Yahoo FinanceDec 11 06:40 ET

The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.

Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.

wallstreetcnNov 17 07:00 ET

Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.

① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.

cls.cnNov 14 20:37 ET

Some Veru Inc. (NASDAQ:VERU) Shareholders Look For Exit As Shares Take 34% Pounding

Simply Wall StNov 14 05:06 ET

Oppenheimer Maintains Veru Inc(VERU.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsNov 5 16:31 ET · Ratings

Veru Announces Meta-analysis Of Body Composition Data From Older Patients With Obesity Which Supports Potential For Enobosarm To Optimize Weight Loss At ObesityWeek

BenzingaNov 5 08:38 ET

Express News | Veru Inc - Topline Results From Phase 2B Quality Trial Expected in January 2025

ReutersNov 5 08:32 ET

Express News | Veru Inc - Enobosarm Generally Well-Tolerated With No Increase in Gastrointestinal Side Effects

ReutersNov 5 08:31 ET

Express News | Veru To Present Meta-Analysis of 4 Previous Randomized Clinical Trials That Support Potential Of Enobosarm To Optimize Weight Loss At ObestiyWeek

BenzingaOct 21 08:41 ET

"Weight-loss miracle drug" causing muscle loss, biotechnology companies like Regeneron Pharmaceuticals (REGN.US) are developing new treatments.

Wegovy and Zepbound, along with other GLP-1 class drugs, have significant effects on weight loss, but this weight loss largely reduces muscle mass.

Zhitong FinanceOct 14 02:42 ET

Weight Loss Drugs Have One Big Issue; These Companies Want to Fix It

Seeking AlphaOct 12 13:58 ET

12 Consumer Staples Stocks Moving In Thursday's After-Market Session

BenzingaOct 10 16:31 ET

Veru Inc (VERU) Q3 2024 Earnings Call Highlights: Strategic Cost Management and Revenue Growth ...

Yahoo FinanceOct 9 17:27 ET

Express News | Veru Inc: On Aug 19, Delivered Notice to Jefferies LLC to Terminate Open Market Sales Agreement

ReutersAug 23 16:07 ET

Earnings Beat: Veru Inc. (NASDAQ:VERU) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Yahoo FinanceAug 11 09:42 ET

Veru Inc | 10-Q: Q3 2024 Earnings Report

SECAug 8 10:49 ET · Announcements

Express News | Veru Inc - Qtrly Net Loss per Basic and Diluted Common Shares Outstanding $0.07

ReutersAug 8 07:25 ET

Veru GAAP EPS of -$0.07, Revenue of $4M

Seeking AlphaAug 8 06:47 ET

Veru 3Q Loss/Shr 7c >VERU

Dow JonesAug 8 06:39 ET

Veru 3Q Research and Development Expenses $4.9M >VERU

Dow JonesAug 8 06:38 ET